Reported Saturday, Takeda's Phase 3 Latitude PsO Data Shows Once-Daily Zasocitinib Achieves 71.4% sPGA 0/1 Response Versus 10.7% For Placebo And 32.1% For Apremilast At Week 16
Benzinga Newsdesk 7 months ago
News
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studiesA significantly greater PASI 75 response rate versus placebo was observed as
- About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies
- A significantly greater PASI 75 response rate versus placebo was observed as early as week 4
- Safety profile consistent with Phase 2b studies with no new safety signals identified